Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Hans F Staehle"'
Autor:
Hans F Staehle, Johannes Heinemann, Albert Gruender, Anne M Omlor, Heike Luise Pahl, Jonas Samuel Jutzi
Publikováno v:
PLoS ONE, Vol 15, Iss 2, p e0228362 (2020)
The histone demethylase JMJD1C is overexpressed in patients with myeloproliferative neoplasms (MPNs) and has been implicated in leukemic stem cell function of MLL-AF9 and HOXA9-driven leukemia. In the emerging field of histone demethylase inhibitors,
Externí odkaz:
https://doaj.org/article/1f9e11ffc55a4feda554b9f11c5c7f33
Autor:
Johannes Heinemann, Hans F. Staehle, Jonas S. Jutzi, Anne M. Omlor, Albert Gruender, Heike L. Pahl
Publikováno v:
PLoS ONE
PLoS ONE, Vol 15, Iss 2, p e0228362 (2020)
PLoS ONE, Vol 15, Iss 2, p e0228362 (2020)
The histone demethylase JMJD1C is overexpressed in patients with myeloproliferative neoplasms (MPNs) and has been implicated in leukemic stem cell function of MLL-AF9 and HOXA9-driven leukemia. In the emerging field of histone demethylase inhibitors,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a42ae103fff51cf78935f9c98e958ce
http://europepmc.org/articles/PMC6999878
http://europepmc.org/articles/PMC6999878
Autor:
Jennifer Dias, Kaitlyn Shank, Maria Kleppe, Julie Teruya-Feldstein, Sudheer Madan Mohan Gambheer, Hans F. Staehle, Hugh Y. Rienhoff, Jonas S. Jutzi, Heike L. Pahl, Ross L. Levine, Christine Dierks
Publikováno v:
HemaSphere, Vol 2, Iss 3 (2018)
HemaSphere
HemaSphere
Supplemental Digital Content is available in the text
Despite recent advances, the myeloproliferative neoplasms (MPNs) are attended by considerable morbidity and mortality. Janus kinase (Jak) inhibitors such as ruxolitinib manage symptoms but do
Despite recent advances, the myeloproliferative neoplasms (MPNs) are attended by considerable morbidity and mortality. Janus kinase (Jak) inhibitors such as ruxolitinib manage symptoms but do
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de9ec4e7330657f1970fd6ef4878e487
http://journals.lww.com/10.1097/HS9.0000000000000054
http://journals.lww.com/10.1097/HS9.0000000000000054
Autor:
Jonas S. Jutzi, Christopher J. Ott, Christoph Koellerer, Albert Gründer, Jan C. Peeken, Heike L. Pahl, Thalia S. Seeger, Heiko Becker, Julius Wehrle, Hans F. Staehle, Monika Gothwal, Elias Schoenwandt, Daniel H. Schanne
Publikováno v:
Blood. 131(18)
The transcription factor "nuclear factor erythroid 2" (NFE2) is overexpressed in the majority of patients with myeloproliferative neoplasms (MPNs). In murine models, elevated NFE2 levels cause an MPN phenotype with spontaneous leukemic transformation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::adb48ed5269dad8642983a2e47ce74f5
https://pubmed.ncbi.nlm.nih.gov/29724716
https://pubmed.ncbi.nlm.nih.gov/29724716